Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response?

Lejla Alic, M van Vliet, CF (Cornelis) van Dijke, Lex Eggermont, J.F. Veenland, Wiro Niessen

Research output: Contribution to journalArticleAcademicpeer-review

86 Citations (Scopus)


This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI (DCE-MRI) using texture analysis methods. The suitability of the coherence and the fractal dimension to monitor tumour response was evaluated in 18 patients with limb sarcomas imaged by DCE-MRI pre-and post-treatment. According to the histopathology, tumours were classified into responders and non-responders. Pharmacokinetic (K(trans)) and heuristic model-based parametric maps (slope, max enhancement, AUC) were computed from the DCE-MRI data. A substantial correlation was found between the pharmacokinetic and heuristic model-based parametric maps: rho = 0.56 for the slope, rho = 0.44 formaximum enhancement, and rho = 0.61 for AUC. From all four parametric maps, the enhancing fraction, and the heterogeneity features (i.e. coherence and fractal dimension) were determined. In terms of monitoring tumour response, using both pre-and post-treatment DCE-MRI, the enhancing fraction and the coherence showed significant differences between the response group and the non-response group (i.e. the highest sensitivity (91%) for K(trans), and the highest specificity (83%) for max enhancement). In terms of treatment prediction, using solely the pre-treatment DCE-MRI, the enhancing fraction and coherence discriminated between responders and non-responders. For prediction, the highest sensitivity (91%) was shared by K(trans), slope and max enhancement, and the highest specificity (71%) was achieved by K(trans). On average, tumours that responded showed a high enhancing fraction and high coherence on the pre-treatment scan. These results suggest that specific heterogeneity features, computed from both pharmacokinetic and heuristic model-based parametric maps, show potential as a biomarker for monitoring tumour response.
Original languageUndefined/Unknown
Pages (from-to)1601-1616
Number of pages16
JournalPhysics in Medicine and Biology
Issue number6
Publication statusPublished - 2011

Research programs

  • EMC MM-03-47-11
  • EMC NIHES-03-30-03

Cite this